亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

培美曲塞 医学 彭布罗利珠单抗 卡铂 内科学 肺癌 肿瘤科 临床终点 危险系数 临床研究阶段 临床试验 外科 顺铂 癌症 化疗 置信区间 免疫疗法
作者
Marina Chiara Garassino,Shirish M. Gadgeel,Giovanna Speranza,Enriqueta Felip,Emilio Esteban,Manuel Dómine,Maximilian J. Hochmair,Steven Powell,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Takayasu Kurata,Jhanelle E. Gray,Paul Schwarzenberger,Erin Jensen,M. Catherine Pietanza
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (11): 1992-1998 被引量:639
标识
DOI:10.1200/jco.22.01989
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680 ). Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed by maintenance pemetrexed until disease progression or unacceptable toxicity. Primary end points were overall survival (OS) and progression-free survival (PFS). Among 616 randomly assigned patients (n = 410, pembrolizumab plus pemetrexed-platinum; n = 206, placebo plus pemetrexed-platinum), median time from random assignment to data cutoff (March 8, 2022) was 64.6 (range, 60.1-72.4) months. Hazard ratio (95% CI) for OS was 0.60 (0.50 to 0.72) and PFS was 0.50 (0.42 to 0.60) for pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed. 5-year OS rates were 19.4% versus 11.3%. Toxicity was manageable. Among 57 patients who completed 35 cycles of pembrolizumab, objective response rate was 86.0% and 3-year OS rate after completing 35 cycles (approximately 5 years after random assignment) was 71.9%. Pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of programmed cell death ligand-1 expression. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care in previously untreated metastatic non–small-cell lung cancer without EGFR/ALK alterations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ccob发布了新的文献求助10
6秒前
7秒前
8秒前
小小昌发布了新的文献求助10
13秒前
SUNny发布了新的文献求助10
14秒前
17秒前
ccob发布了新的文献求助10
21秒前
欣慰的代桃完成签到,获得积分10
29秒前
zilicai的应助被纯情的阁采纳,获得100
41秒前
SUNny完成签到,获得积分10
51秒前
风趣的莫英完成签到,获得积分10
1分钟前
NexusExplorer的应助被科研通管家采纳,获得30
1分钟前
1分钟前
天天快乐的应助被科研通管家采纳,获得50
1分钟前
感性的又菡完成签到,获得积分10
1分钟前
1分钟前
标致访旋完成签到,获得积分10
1分钟前
风华完成签到,获得积分10
2分钟前
孔秋词完成签到,获得积分10
2分钟前
感性的远航完成签到,获得积分10
2分钟前
刻苦的刚完成签到,获得积分10
2分钟前
年轻靖巧完成签到,获得积分10
2分钟前
2分钟前
朝花惜拾完成签到 ,获得积分10
2分钟前
搜集达人的应助被科研通管家采纳,获得10
3分钟前
奔跑的应助被科研通管家采纳,获得10
3分钟前
迷路飞凤完成签到,获得积分10
3分钟前
3分钟前
漂亮的又槐完成签到,获得积分10
3分钟前
3分钟前
3分钟前
英俊的铭的应助被小小昌采纳,获得10
3分钟前
3分钟前
3分钟前
噗愣噗愣地刚发芽完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
大胆紫烟完成签到,获得积分10
4分钟前
SEN完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179877
求助须知:如何正确求助?哪些是违规求助? 9570060
关于积分的说明 21808221
捐赠科研通 7775626
什么是DOI,文献DOI怎么找? 3433171
关于科研通互助平台的介绍 2557308
邀请新用户注册赠送积分活动 2478846